[{"orgOrder":0,"company":"Nuravax","sponsor":"Arvax","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"AV-1959R","moa":"Amyloid-beta\/Tau","graph1":"Neurology","graph2":"Phase I","graph3":"Nuravax","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular","sponsorNew":"Nuravax \/ Arvax","highestDevelopmentStatusID":"6","companyTruncated":"Nuravax \/ Arvax"},{"orgOrder":0,"company":"Nuravax","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Funding","leadProduct":"AV-1959R","moa":"||Amyloid-beta\/Tau","graph1":"Neurology","graph2":"Phase I","graph3":"Nuravax","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular","sponsorNew":"Nuravax \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"Nuravax \/ National Institutes of Health"},{"orgOrder":0,"company":"Nuravax","sponsor":"National Institute on Aging | Institute for Molecular Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"DUVAX","moa":"Amyloid-beta-plaque","graph1":"Neurology","graph2":"Phase I","graph3":"Nuravax","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nuravax \/ National Institute on Aging | Institute for Molecular Medicine","highestDevelopmentStatusID":"6","companyTruncated":"Nuravax \/ National Institute on Aging | Institute for Molecular Medicine"}]

Find Clinical Drug Pipeline Developments & Deals by Nuravax

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          ESCRS
                          Not Confirmed
                          ESCRS
                          Not Confirmed

                          Lead Product(s) : DUVAX

                          Therapeutic Area : Neurology

                          Study Phase : Phase I

                          Sponsor : National Institute on Aging | Institute for Molecular Medicine

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : DUVAX is a Vaccine drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Alzheimer Disease.

                          Product Name : Undisclosed

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          August 26, 2025

                          Lead Product(s) : DUVAX

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : National Institute on Aging | Institute for Molecular Medicine

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          ESCRS
                          Not Confirmed
                          ESCRS
                          Not Confirmed

                          Details : The funding aims to advance the clinical development of Duvax, the first dual-target. It is being evaluated for the treatment of Alzheimer Disease.

                          Product Name : Duvax

                          Product Type : Vaccine

                          Upfront Cash : Undisclosed

                          May 05, 2025

                          Lead Product(s) : AV-1959R,AV-1980R

                          Therapeutic Area : Neurology

                          Highest Development Status : IND Enabling

                          Sponsor : National Institutes of Health

                          Deal Size : $3.0 million

                          Deal Type : Funding

                          blank

                          03

                          ESCRS
                          Not Confirmed
                          ESCRS
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Abeta

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          February 18, 2025

                          Lead Product(s) : AV-1959R

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : Arvax

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank